FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Alert on Hyperbaric Oxygen Devices

FDA alerts health care providers and facilities about the safe use of hyperbaric oxygen therapy devices following reports of serious injuries and deat...

latest-news-card-1
Human Drugs

FDA Broadens Use of Amgens Repatha

FDA expands the approved use of Amgens cholesterol-lowering drug Repatha (evolocumab) to include adults at increased risk of major adverse cardiovascu...

latest-news-card-1
Biologics

Argenx Plans sBLA for Vyvgart in Myasthenia Gravis

Argenx says it will seek expanded approval for Vyvgart (efgartigimod alfa-fcab) to include adults with acetylcholine receptor antibody seronegative ge...

latest-news-card-1
Human Drugs

Vanda Urges Makary to Intercede in Generic Dispute

Vanda Pharmaceuticals urges FDA commissioner Marty Makary to reconsider a recent agency decision upholding approvals of two generic versions of Hetlio...

Medical Devices

AdvaMed Urges FDA/CMS Alignment on Breakthrough Devices

AdvaMed and other device stakeholders urge the Centers for Medicare & Medicaid Services to overhaul how it covers new device technologies, warning tha...

latest-news-card-1
Human Drugs

Boston Scientific Recalls Defective Stent System

Boston Scientific recalls (Class 1) its Carotid Wallstent Monorail Endoprosthesis due to a manufacturing defect that created an inner lumen smaller th...

latest-news-card-1
Human Drugs

FDA 483 Shows GMP Troubles at Plant Making Eylea

A new Form FDA-483 cites significant GMP issues at the plant that makes Regenerons Eylea HD (aflibercept), delaying review of two related regulatory s...

latest-news-card-1
Medical Devices

FDA Clears Signos OTC Glucose Monitor

FDA clears a Signos 510(k) for what the company says is the first over-the-counter glucose monitoring system designed specifically for weight manageme...

latest-news-card-1
Human Drugs

FDA Moves to Daily Drug Adverse Event Data

FDA is now publishing drug safety data on a daily basis, a shift the agency says will give the public faster access to information about adverse event...

latest-news-card-1
Human Drugs

FDA Orphan Status for Keros Duchenne Candidate

FDA grants Keros Therapeutics an orphan drug designation for its investigational therapy KER-065 and its use in treating Duchenne muscular dystrophy.